Cancer CDx collaboration
REHOVOT, Israel & BOULDER, Colo.—Under the auspices of a new strategic collaboration, ArcherDX Inc. and Ayala Pharmaceuticals will work together to develop companion diagnostic tests for cancers with Notch activating mutations and fusions. No financial details were released.
“Working closely with biopharma partners to help bring biomarker-driven therapies to individuals diagnosed with cancer is central to our mission to improve access to genomic-based medicine. Partnerships with progressive companies such as Ayala, who can leverage our unique ability to provide companion diagnostic solutions from both tissue and blood-based specimens and deploy them at scale as in-vitro diagnostics to laboratories around the world, is essential to achieving this mission,” said Jason Myers, co-founder and CEO of ArcherDX. “We’re proud to support Ayala in their pursuit of meaningful new precision oncology treatment options.”